Emergent BioSolutions Inc. (NYSE:EBS) Shares Acquired by Two Sigma Advisers LP

Two Sigma Advisers LP raised its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 14.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 656,500 shares of the biopharmaceutical company's stock after buying an additional 81,000 shares during the period. Two Sigma Advisers LP owned about 1.21% of Emergent BioSolutions worth $6,276,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of EBS. Covestor Ltd raised its stake in shares of Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 2,893 shares during the period. Northern Trust Corp lifted its stake in shares of Emergent BioSolutions by 2.6% during the fourth quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company's stock worth $1,395,000 after purchasing an additional 3,692 shares in the last quarter. LPL Financial LLC boosted its position in shares of Emergent BioSolutions by 34.5% in the fourth quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock worth $145,000 after buying an additional 3,875 shares during the period. Federated Hermes Inc. grew its stake in shares of Emergent BioSolutions by 2.2% in the fourth quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock valued at $2,656,000 after buying an additional 6,058 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the fourth quarter valued at about $63,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Emergent BioSolutions Stock Down 1.3%

Shares of NYSE:EBS traded down $0.09 during trading on Thursday, hitting $6.42. The company's stock had a trading volume of 392,536 shares, compared to its average volume of 1,847,664. The company has a market capitalization of $348.19 million, a PE ratio of -1.57 and a beta of 2.09. Emergent BioSolutions Inc. has a fifty-two week low of $4.02 and a fifty-two week high of $15.10. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The stock's 50-day moving average price is $5.28 and its two-hundred day moving average price is $7.62.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.22. The company had revenue of $222.20 million for the quarter, compared to the consensus estimate of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. As a group, sell-side analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions announced that its Board of Directors has initiated a stock buyback plan on Monday, March 31st that permits the company to buyback $50.00 million in outstanding shares. This buyback authorization permits the biopharmaceutical company to buy up to 19% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

Insider Buying and Selling

In other news, Director Neal Franklin Fowler sold 35,000 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now owns 101,100 shares in the company, valued at approximately $589,413. This represents a 25.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Keith Katkin sold 7,844 shares of Emergent BioSolutions stock in a transaction dated Friday, May 23rd. The stock was sold at an average price of $6.30, for a total value of $49,417.20. Following the completion of the transaction, the director now owns 86,431 shares of the company's stock, valued at $544,515.30. This trade represents a 8.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

EBS has been the subject of a number of analyst reports. Wall Street Zen cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday, April 1st.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.